BR0317538A - Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo - Google Patents
Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduoInfo
- Publication number
- BR0317538A BR0317538A BR0317538-3A BR0317538A BR0317538A BR 0317538 A BR0317538 A BR 0317538A BR 0317538 A BR0317538 A BR 0317538A BR 0317538 A BR0317538 A BR 0317538A
- Authority
- BR
- Brazil
- Prior art keywords
- myostatin
- individual
- lean
- disorder
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
Abstract
"AGENTE LIGANTE, SEQuêNCIA DE POLINUCLEOTìDEO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, COMPOSIçãO FARMACêUTICA, E, MéTODOS DE INIBIR A ATIVIDADE DE MIOSTATINA, DE AUMENTAR A MASSA MUSCULAR MAGRA E A RAZãO DE MASSA MUSCULAR MAGRA PARA GORDURA, DE TRATAR UMA DOENçA DE EMACIAçãO MUSCULAR E UM DISTúRBIO METABóLICO RELACIONADO COM MIOSTATINA EM UM INDIVìDUO, DE DETECTAR E MEDIR MIOSTATINA EM UMA AMOSTRA, E, DE DIAGNOSTICAR UM DISTúRBIO RELACIONADO COM MIOSTATINA EM UM INDIVìDUO". A presente invenção proporciona agentes ligantes compreendendo peptídeos capazes de ligar em miostatina e inibirem sua atividade. Em uma modalidade o agente ligante compreende pelo menos um peptídeo ligante de miostatina ligado direta ou indiretamente a pelo menos um veículo tal como um polímero ou um domínio Fc. Os agentes ligantes da presente invenção produzidos aumentaram a massa muscular magra quando administrados aos animais e diminuíram as razões de gordura para músculo. Composições terapêuticas contendo os agentes ligantes da presente invenção são úteis para tratar distúrbios de emaciação muscular e outros distúrbios metabólicos incluindo diabetes e obesidade.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43592302P | 2002-12-20 | 2002-12-20 | |
PCT/US2003/040781 WO2004058988A2 (en) | 2002-12-20 | 2003-12-19 | Binding agents which inhibit myostatin |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0317538A true BR0317538A (pt) | 2005-11-29 |
Family
ID=32682298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0317538-3A BR0317538A (pt) | 2002-12-20 | 2003-12-19 | Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo |
Country Status (28)
Country | Link |
---|---|
US (7) | US7511012B2 (pt) |
EP (2) | EP2272864A3 (pt) |
JP (3) | JP4959137B2 (pt) |
KR (9) | KR20120060250A (pt) |
CN (2) | CN101287484B (pt) |
AR (2) | AR042545A1 (pt) |
AT (1) | ATE496938T1 (pt) |
AU (2) | AU2003301195B2 (pt) |
BR (1) | BR0317538A (pt) |
CA (2) | CA2510893C (pt) |
CY (1) | CY1111388T1 (pt) |
DE (1) | DE60335915D1 (pt) |
DK (1) | DK1581649T3 (pt) |
EA (1) | EA009056B1 (pt) |
ES (1) | ES2359562T3 (pt) |
HK (1) | HK1084419A1 (pt) |
IL (3) | IL169168A0 (pt) |
ME (1) | MEP57508A (pt) |
MX (1) | MXPA05006521A (pt) |
NO (2) | NO335982B1 (pt) |
NZ (1) | NZ541253A (pt) |
PL (1) | PL383616A1 (pt) |
PT (1) | PT1581649E (pt) |
RS (1) | RS52815B (pt) |
SI (1) | SI1581649T1 (pt) |
TW (1) | TWI328456B (pt) |
WO (1) | WO2004058988A2 (pt) |
ZA (1) | ZA200505481B (pt) |
Families Citing this family (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69934425T2 (de) | 1998-10-23 | 2007-09-27 | Amgen Inc., Thousand Oaks | Thrombopoietin substitute |
TWI329129B (en) | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
KR20040096592A (ko) * | 2002-02-21 | 2004-11-16 | 와이어쓰 | 폴리스타틴 도메인을 포함하는 단백질 |
IL163525A0 (en) | 2002-02-21 | 2005-12-18 | Wyeth Corp | A follistatin domain containing protein |
US7193069B2 (en) * | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
CA2498044A1 (en) * | 2002-09-16 | 2004-03-25 | Wyeth | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
PT1581649E (pt) * | 2002-12-20 | 2011-04-13 | Amgen Inc | Agentes de ligação que inibem a miostatina |
BRPI0410927A (pt) * | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
EP2256134B1 (en) | 2003-11-13 | 2014-01-08 | Hanmi Science Co., Ltd. | IgG Fc fragment for a drug carrier and method for the preparation thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
EP1699820A2 (en) | 2003-12-31 | 2006-09-13 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
CA2567810A1 (en) * | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
CA2572765C (en) * | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
SI1797127T1 (sl) * | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modificirane fc-molekule |
AU2005323087A1 (en) | 2004-12-30 | 2006-07-13 | Schering-Plough Pty. Limited | Neutralizing epitope-based growth enhancing vaccine |
NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
WO2006107611A2 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
BRPI0609449A2 (pt) * | 2005-03-23 | 2010-04-06 | Wyeth Corp | detecção de agentes de modulação de gdf-8 |
JP2008543839A (ja) | 2005-06-14 | 2008-12-04 | アムジェン インコーポレーテッド | 自己緩衝タンパク質製剤 |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
EP1951756B1 (en) | 2005-10-06 | 2015-01-07 | Eli Lilly And Company | Anti-myostatin antibodies |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US20090163579A1 (en) * | 2005-10-14 | 2009-06-25 | Daniel Raederstorff | Novel use of nutraceutical compositions |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
WO2007067616A2 (en) * | 2005-12-06 | 2007-06-14 | Amgen Inc | Uses of myostatin antagonists |
US9283260B2 (en) * | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
KR101123531B1 (ko) * | 2006-09-05 | 2012-04-20 | 일라이 릴리 앤드 캄파니 | 항-마이오스타틴 항체 |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
EP2099471A2 (en) * | 2006-12-08 | 2009-09-16 | Acceleron Pharma, Inc. | Uses of cerberus, coco and derivatives thereof |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
US8420779B2 (en) | 2007-05-22 | 2013-04-16 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
WO2009015345A1 (en) * | 2007-07-25 | 2009-01-29 | Amgen Inc. | Pharmaceutical compositions comprising fc fusion proteins |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
PL2170396T3 (pl) | 2007-08-03 | 2017-07-31 | Summit (Oxford) Limited | Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a |
US20110097318A1 (en) * | 2007-08-31 | 2011-04-28 | Amgen Inc. | Solid-State Protein Formulation |
EP2205280B1 (en) | 2007-09-27 | 2019-09-04 | Amgen Inc. | Pharmaceutical formulations |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
WO2009137880A1 (en) | 2008-05-14 | 2009-11-19 | Agriculture Victoria Services Pty Ltd | Use of angiogenin or angiogenin agonists for treating diseases and disorders |
EP2370463B1 (en) | 2008-11-26 | 2016-08-31 | Amgen Inc. | A stabilized variant of activin iib receptor |
WO2011005488A1 (en) | 2009-06-22 | 2011-01-13 | Amgen Inc. | Refolding proteins using a chemically controlled redox state |
US8945511B2 (en) * | 2009-06-25 | 2015-02-03 | Paul Weinberger | Sensitive methods for detecting the presence of cancer associated with the over-expression of galectin-3 using biomarkers derived from galectin-3 |
EP2445924B2 (en) | 2009-06-25 | 2023-12-13 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
AU2011265005B2 (en) | 2010-06-07 | 2015-04-09 | Amgen Inc. | Drug delivery device |
CN103221426B (zh) | 2010-08-16 | 2016-01-13 | 安姆根公司 | 结合肌肉生长抑制素的抗体、组合物和方法 |
CA2831100C (en) | 2011-03-31 | 2020-02-18 | Mark Dominis Holt | Vial adapter and system |
EP4074355A1 (en) | 2011-04-20 | 2022-10-19 | Amgen Inc. | Autoinjector apparatus |
US9758548B2 (en) * | 2011-05-11 | 2017-09-12 | Technion Research & Development Foundation Limited | Anti-microbial peptides and uses of same |
CA2851521C (en) | 2011-10-14 | 2020-09-22 | Amgen Inc. | Injector and method of assembly |
ES2693508T3 (es) | 2011-10-26 | 2018-12-12 | Amgen Inc. | Métodos para reducir o eliminar la modificación y la degradación de proteínas debidas a una exposición a luz UV |
FR2982860B1 (fr) * | 2011-11-18 | 2015-07-10 | Ass Fr Contre Les Myopathies | Utilisation de la fibromoduline et du lumican pour augmenter la masse musculaire |
EA201491231A8 (ru) | 2011-12-19 | 2015-01-30 | Амген Инк. | Варианты полипептидов рецептора активина и их применение |
AU2013240183B2 (en) | 2012-03-26 | 2016-10-20 | Axcella Health Inc. | Charged nutritive proteins and methods |
WO2013148328A1 (en) | 2012-03-26 | 2013-10-03 | Pronutria, Inc. | Nutritive proteins and methods |
US9700071B2 (en) | 2012-03-26 | 2017-07-11 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
CA2868473A1 (en) | 2012-03-26 | 2013-10-03 | Pronutria, Inc. | Nutritive fragments, proteins and methods |
AU2013204740C1 (en) | 2012-05-10 | 2015-10-01 | Agriculture Victoria Services Pty Ltd | Methods of treating cancer using angiogenin or an angiogenin agonist |
WO2014039189A1 (en) | 2012-08-01 | 2014-03-13 | Mcnally Elizabeth | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
EP2922590B1 (en) | 2012-11-21 | 2020-02-05 | Amgen Inc. | Drug delivery device |
JP6143270B2 (ja) * | 2013-01-31 | 2017-06-07 | 学校法人東京薬科大学 | マイオスタチン阻害ペプチド |
CA2899889A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an anti-activin-a compound to a subject |
TWI639449B (zh) | 2013-03-15 | 2018-11-01 | 美商安美基公司 | 用於注射器之匣盒 |
WO2014144096A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
AU2014238267B2 (en) | 2013-03-22 | 2019-08-15 | Amgen Inc. | Injector and method of assembly |
KR101523065B1 (ko) * | 2013-06-19 | 2015-05-27 | 한국기초과학지원연구원 | 입자크기가 제어된 금 나노입자의 제조방법 및 제조된 금 나노입자를 이용한 비색식 강산 검출방법 |
TW201601741A (zh) * | 2013-09-09 | 2016-01-16 | 品特生物療法有限公司 | 用於治療esrd病患之pew的肌肉生長抑制素拮抗劑 |
AU2014324901A1 (en) | 2013-09-25 | 2016-05-19 | Axcella Health Inc. | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control |
CA2920894C (en) | 2013-10-24 | 2023-03-14 | Amgen Inc. | Injector and method of assembly |
CA2926110C (en) | 2013-10-24 | 2023-05-23 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
US10994112B2 (en) | 2014-02-05 | 2021-05-04 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
EP3139977B1 (en) | 2014-05-07 | 2021-02-17 | Amgen Inc. | Autoinjector with shock reducing elements |
WO2015187802A1 (en) | 2014-06-03 | 2015-12-10 | Amgen Inc. | Devices and methods for assisting a user of a drug delivery device |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
EP3943135A3 (en) | 2014-10-14 | 2022-06-29 | Amgen Inc. | Drug injection device with visual and audible indicators |
EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
US10799630B2 (en) | 2014-12-19 | 2020-10-13 | Amgen Inc. | Drug delivery device with proximity sensor |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
EP3556411B1 (en) | 2015-02-17 | 2021-06-30 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
US11806509B2 (en) | 2015-02-27 | 2023-11-07 | Amgen Inc. | Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement |
AU2016252887B2 (en) * | 2015-04-23 | 2021-08-12 | Baker Heart and Diabetes Institute | Smad7 gene delivery as a therapeutic |
CN106191215B (zh) | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
EP4209499A1 (en) | 2015-08-13 | 2023-07-12 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
ES2755717T3 (es) | 2015-12-09 | 2020-04-23 | Amgen Inc | Autoinyector con tapa de señalización |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
ES2814287T3 (es) | 2016-03-15 | 2021-03-26 | Amgen Inc | Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco |
RU2613420C1 (ru) * | 2016-04-13 | 2017-03-16 | Сергей Михайлович Юдин | Рекомбинантный белок Мио-ГСД, способ его получения, инъекционный препарат для повышения мышечной массы сельскохозяйственных животных, птицы и животных семейства псовых, а также способ использования препарата |
CN115975044A (zh) * | 2016-04-25 | 2023-04-18 | 戊瑞治疗有限公司 | 用于治疗病理性肌肉损失和虚弱的nope |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
US11389588B2 (en) | 2016-05-02 | 2022-07-19 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
JP7309363B2 (ja) | 2016-05-13 | 2023-07-18 | アムジエン・インコーポレーテツド | バイアル・スリーブ組立体 |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
US10150115B2 (en) * | 2016-07-21 | 2018-12-11 | Spacepharma SA | System and method for rehydrating powder and delivering the rehydrated powder to a reactor |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
EA201990998A1 (ru) | 2016-10-21 | 2019-11-29 | Фармацевтические составы и способы их получения | |
WO2018081234A1 (en) | 2016-10-25 | 2018-05-03 | Amgen Inc. | On-body injector |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
HRP20230308T1 (hr) * | 2017-01-06 | 2023-05-12 | Scholar Rock, Inc. | Liječenje metaboličkih bolesti putem inhibiranja aktivacije miostatina |
CA3049780A1 (en) | 2017-01-17 | 2018-07-26 | Amgen Inc. | Injection devices and related methods of use and assembly |
MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
MX2019009625A (es) | 2017-02-17 | 2019-10-09 | Amgen Inc | Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje. |
AU2018231107B2 (en) | 2017-03-06 | 2023-04-20 | Amgen Inc. | Drug delivery device with activation prevention feature |
WO2018164829A1 (en) | 2017-03-07 | 2018-09-13 | Amgen Inc. | Needle insertion by overpressure |
MX2019010671A (es) | 2017-03-09 | 2019-10-21 | Amgen Inc | Mecanismo de insercion para dispositivo de administracion de farmacos. |
EA037969B1 (ru) | 2017-03-28 | 2021-06-17 | Эмджен Инк. | Система и способ сборки штока поршня и шприца |
WO2018226515A1 (en) | 2017-06-08 | 2018-12-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
CN110709121B (zh) | 2017-06-08 | 2022-06-24 | 安进公司 | 扭矩驱动式药物递送装置 |
MA49447A (fr) | 2017-06-22 | 2020-04-29 | Amgen Inc | Réduction des impacts/chocs d'activation d'un dispositif |
EP3641861A1 (en) | 2017-06-23 | 2020-04-29 | Amgen Inc. | Electronic drug delivery device comprising a cap activated by a switch assembly |
MA49562A (fr) | 2017-07-14 | 2020-05-20 | Amgen Inc | Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion |
MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
MA49838A (fr) | 2017-08-09 | 2020-06-17 | Amgen Inc | Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre |
WO2019036181A1 (en) | 2017-08-18 | 2019-02-21 | Amgen Inc. | BODY INJECTOR WITH STERILE ADHESIVE PATCH |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
EP4257164A3 (en) | 2017-10-06 | 2024-01-17 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
MA50348A (fr) | 2017-10-09 | 2020-08-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé |
MA50528A (fr) | 2017-11-03 | 2020-09-09 | Amgen Inc | Systèmes et approches pour stériliser un dispositif d'administration de médicament |
US20200338271A1 (en) | 2017-11-06 | 2020-10-29 | Amgen Inc. | Fill-finish assemblies and related methods |
EP3706830A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019094138A1 (en) | 2017-11-10 | 2019-05-16 | Amgen Inc. | Plungers for drug delivery devices |
CN111263651B (zh) | 2017-11-16 | 2022-06-17 | 安进公司 | 具有停顿和终点检测的自动注射器 |
MA50904A (fr) | 2017-11-16 | 2020-09-23 | Amgen Inc | Mécanisme d'insertion d'aiguille pour dispositif d'administration de médicament |
EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
KR102042352B1 (ko) | 2018-07-16 | 2019-11-07 | 강릉원주대학교산학협력단 | 땅콩 껍질 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물 |
KR102259645B1 (ko) | 2018-07-16 | 2021-06-02 | 강릉원주대학교산학협력단 | 구멍쇠미역 추출물을 포함하는 근력강화 또는 근감소증의 예방 및 치료용 조성물 |
MA53375A (fr) | 2018-07-24 | 2021-06-02 | Amgen Inc | Dispositifs d'administration pour l'administration de médicaments |
US20210369982A1 (en) | 2018-07-24 | 2021-12-02 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020028009A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
JP2022500095A (ja) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | インターベンション投薬システム及び方法 |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
US20200101229A1 (en) | 2018-10-02 | 2020-04-02 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
AR116607A1 (es) | 2018-10-05 | 2021-05-26 | Amgen Inc | Dispositivo de administración de fármacos con indicador de dosis |
EA202191038A1 (ru) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | Способ платформенной сборки для устройства доставки лекарственного средства |
BR112021007016A2 (pt) | 2018-10-15 | 2021-07-13 | Amgen Inc. | dispositivo de administração de fármaco tendo mecanismo de amortecimento |
WO2020086635A1 (en) | 2018-10-23 | 2020-04-30 | Amgen Inc. | Automatic calibration and automatic maintenance of raman spectroscopic models for real-time predictions |
US20220031953A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial needle retraction |
MA54048A (fr) | 2018-11-01 | 2022-02-09 | Amgen Inc | Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament |
AU2019370159A1 (en) | 2018-11-01 | 2021-04-22 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
JP2022514778A (ja) | 2018-12-21 | 2022-02-15 | ノースウェスタン ユニバーシティ | 筋膜損傷の予防および治療におけるアネキシンの使用 |
WO2020139977A1 (en) | 2018-12-26 | 2020-07-02 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
EP3958934A1 (en) | 2019-04-24 | 2022-03-02 | Amgen Inc. | Syringe sterilization verification assemblies and methods |
JP2022545227A (ja) | 2019-08-23 | 2022-10-26 | アムジエン・インコーポレーテツド | 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法 |
US20230071627A1 (en) | 2020-02-03 | 2023-03-09 | Amgen Inc. | Multivariate Bracketing Approach for Sterile Filter Validation |
AU2022279223A1 (en) | 2021-05-21 | 2023-10-19 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
WO2023076318A1 (en) | 2021-10-27 | 2023-05-04 | Amgen Inc. | Deep learning-based prediction for monitoring of pharmaceuticals using spectroscopy |
WO2023096232A1 (ko) * | 2021-11-25 | 2023-06-01 | (주)네오크레마 | 신규 펩티드 및 이의 용도 |
WO2023096233A1 (ko) * | 2021-11-25 | 2023-06-01 | (주)네오크레마 | 신규 펩티드 및 이의 용도 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
AU2879292A (en) * | 1991-10-08 | 1993-05-03 | Duke University | Peptides corresponding to antigenic determinants of htlv |
EP0690873B1 (en) | 1993-03-19 | 2003-06-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US7393682B1 (en) | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
WO1999002667A1 (en) | 1997-07-14 | 1999-01-21 | University Of Liege | Mutations in the myostation gene cause double-muscling in mammals |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
GB2333706A (en) * | 1998-02-02 | 1999-08-04 | Merck & Co Inc | Method for increasing muscle mass in animals |
US6369201B1 (en) * | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
ES2330062T3 (es) * | 1998-05-06 | 2009-12-03 | Metamorphix, Inc. | Procedimientos para tratar la diabetes por inhibicion de gdf-8. |
AU5143099A (en) * | 1998-07-30 | 2000-02-21 | Universite De Montreal | Protein fragment complementation assays for the detection of biological or drug interactions |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
JP2003517580A (ja) * | 1999-01-21 | 2003-05-27 | メタモーフイクス・インコーポレーテツド | 増殖分化因子インヒビター及びそれらの用途 |
US6284882B1 (en) * | 1999-06-10 | 2001-09-04 | Abbott Laboratories | Myostatin gene promoter and inhibition of activation thereof |
CA2379852A1 (en) * | 1999-07-20 | 2001-01-25 | Pharmexa A/S | Method for down-regulating gdf-8 activity |
EP1593689A3 (en) | 2000-01-18 | 2006-04-05 | Ovita Limited | Myostatin and mimetics thereof |
AU2000239309A1 (en) * | 2000-03-29 | 2001-10-08 | Dgi Biotechnologies Llc | Insulin and igf-1 receptor agonists and antagonists |
WO2002055544A2 (en) * | 2000-12-23 | 2002-07-18 | Dyax Corp | Fibrin binding polypeptides useful inter alia in medical imaging processes |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
PT1581649E (pt) * | 2002-12-20 | 2011-04-13 | Amgen Inc | Agentes de ligação que inibem a miostatina |
BRPI0410927A (pt) | 2003-06-02 | 2006-06-27 | Wyeth Corp | métodos terapêuticos e profiláticos para distúrbios neuromusculares |
EP1677816B1 (en) | 2003-10-06 | 2014-03-12 | Paranta Biosciences Limited | Follistatin for use in down-regulation an inflammatory response |
EP2256134B1 (en) | 2003-11-13 | 2014-01-08 | Hanmi Science Co., Ltd. | IgG Fc fragment for a drug carrier and method for the preparation thereof |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
WO2005094446A2 (en) | 2004-03-23 | 2005-10-13 | Eli Lilly And Company | Anti-myostatin antibodies |
SI1797127T1 (sl) * | 2004-09-24 | 2017-09-29 | Amgen Inc. | Modificirane fc-molekule |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
AU2006283725B2 (en) | 2005-08-19 | 2012-02-16 | The Trustees Of The University Of Pennsylvania | Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
-
2003
- 2003-12-19 PT PT03814258T patent/PT1581649E/pt unknown
- 2003-12-19 SI SI200331987T patent/SI1581649T1/sl unknown
- 2003-12-19 ES ES03814258T patent/ES2359562T3/es not_active Expired - Lifetime
- 2003-12-19 JP JP2004563875A patent/JP4959137B2/ja not_active Expired - Fee Related
- 2003-12-19 TW TW092136171A patent/TWI328456B/zh not_active IP Right Cessation
- 2003-12-19 KR KR1020127013452A patent/KR20120060250A/ko not_active Application Discontinuation
- 2003-12-19 CN CN2003801099052A patent/CN101287484B/zh not_active Expired - Fee Related
- 2003-12-19 NZ NZ541253A patent/NZ541253A/en not_active IP Right Cessation
- 2003-12-19 KR KR1020117016431A patent/KR20110086881A/ko not_active Application Discontinuation
- 2003-12-19 KR KR1020137033417A patent/KR20140004805A/ko not_active Application Discontinuation
- 2003-12-19 AR ARP030104727A patent/AR042545A1/es not_active Application Discontinuation
- 2003-12-19 EP EP10184770A patent/EP2272864A3/en not_active Withdrawn
- 2003-12-19 DK DK03814258.4T patent/DK1581649T3/da active
- 2003-12-19 DE DE60335915T patent/DE60335915D1/de not_active Expired - Lifetime
- 2003-12-19 PL PL383616A patent/PL383616A1/pl unknown
- 2003-12-19 CN CN2011103080199A patent/CN102382172A/zh active Pending
- 2003-12-19 AU AU2003301195A patent/AU2003301195B2/en not_active Ceased
- 2003-12-19 KR KR1020157000046A patent/KR20150013350A/ko not_active Application Discontinuation
- 2003-12-19 AT AT03814258T patent/ATE496938T1/de active
- 2003-12-19 CA CA2510893A patent/CA2510893C/en not_active Expired - Fee Related
- 2003-12-19 CA CA2774928A patent/CA2774928A1/en not_active Abandoned
- 2003-12-19 MX MXPA05006521A patent/MXPA05006521A/es active IP Right Grant
- 2003-12-19 BR BR0317538-3A patent/BR0317538A/pt not_active Application Discontinuation
- 2003-12-19 KR KR1020127008700A patent/KR20120037517A/ko not_active Application Discontinuation
- 2003-12-19 KR KR1020167010048A patent/KR20160045936A/ko not_active Application Discontinuation
- 2003-12-19 KR KR1020057011611A patent/KR101304718B1/ko not_active IP Right Cessation
- 2003-12-19 WO PCT/US2003/040781 patent/WO2004058988A2/en active Application Filing
- 2003-12-19 US US10/742,379 patent/US7511012B2/en not_active Expired - Fee Related
- 2003-12-19 ME MEP-575/08A patent/MEP57508A/xx unknown
- 2003-12-19 EA EA200501000A patent/EA009056B1/ru not_active IP Right Cessation
- 2003-12-19 RS YU20050530A patent/RS52815B/sr unknown
- 2003-12-19 KR KR1020137007048A patent/KR20130036378A/ko not_active Application Discontinuation
- 2003-12-19 KR KR1020157024227A patent/KR20150107899A/ko not_active Application Discontinuation
- 2003-12-19 EP EP03814258A patent/EP1581649B1/en not_active Expired - Lifetime
-
2005
- 2005-06-15 IL IL169168A patent/IL169168A0/en not_active IP Right Cessation
- 2005-07-07 ZA ZA200505481A patent/ZA200505481B/xx unknown
- 2005-07-19 NO NO20053545A patent/NO335982B1/no not_active IP Right Cessation
-
2006
- 2006-04-03 HK HK06104082.5A patent/HK1084419A1/xx not_active IP Right Cessation
-
2009
- 2009-01-30 US US12/322,369 patent/US7803923B2/en not_active Expired - Fee Related
- 2009-02-10 US US12/322,977 patent/US7928075B2/en not_active Expired - Fee Related
-
2010
- 2010-02-25 JP JP2010040110A patent/JP2010193888A/ja active Pending
- 2010-04-07 AU AU2010201389A patent/AU2010201389A1/en not_active Abandoned
- 2010-04-22 IL IL205266A patent/IL205266A0/en unknown
- 2010-04-22 IL IL205265A patent/IL205265A/en not_active IP Right Cessation
- 2010-08-23 US US12/806,880 patent/US8071538B2/en not_active Expired - Fee Related
-
2011
- 2011-04-15 CY CY20111100378T patent/CY1111388T1/el unknown
- 2011-12-02 US US13/310,661 patent/US20120083442A1/en not_active Abandoned
-
2012
- 2012-10-02 JP JP2012220159A patent/JP2013048622A/ja not_active Withdrawn
- 2012-11-20 US US13/682,580 patent/US8920798B2/en not_active Expired - Fee Related
-
2014
- 2014-09-08 AR ARP140103349A patent/AR097588A2/es unknown
- 2014-10-30 US US14/528,959 patent/US20150175687A1/en not_active Abandoned
- 2014-12-05 NO NO20141479A patent/NO20141479L/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0317538A (pt) | Agente ligante, sequência de polinucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos de inibir a atividade de miostatina, de aumentar a massa muscular magra e a razão de massa muscular magra para gordura, de tratar uma doença de emaciação muscular e um distúrbio metabólico relacionado com miostatina em um indivìduo, de detectar e medir miostatina em uma amostra, e, de diagnosticar um distúrbio relacionado com miostatina em um indivìduo | |
Kilroe et al. | Short-term muscle disuse induces a rapid and sustained decline in daily myofibrillar protein synthesis rates | |
Tanner et al. | Age‐related differences in lean mass, protein synthesis and skeletal muscle markers of proteolysis after bed rest and exercise rehabilitation | |
Gundermann et al. | Activation of mTORC1 signaling and protein synthesis in human muscle following blood flow restriction exercise is inhibited by rapamycin | |
Duchateau et al. | Neural adaptations with chronic activity patterns in able-bodied humans | |
van der Hoop et al. | Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer | |
Jankowska | Effects of 4-aminopyridine on transmission in excitatory and inhibitory synapses in the spinal cord | |
Wall et al. | Neuromuscular electrical stimulation increases muscle protein synthesis in elderly type 2 diabetic men | |
Leibel et al. | Biologic responses to weight loss and weight regain: report from an American Diabetes Association research symposium | |
Fang et al. | Parameter-specific analgesic effects of electroacupuncture mediated by degree of regulation TRPV1 and P2X3 in inflammatory pain in rats | |
BR9710586A (pt) | Composição para administração entérica, processos para intensificar a resistência fìsica de um mamìfmamìfero, para o tratamento de osteoporose em um ser humano, para o tratamento de catabiolismo em um ser humano, causado pela aidas ou pelo câncer e para melhorar os efeitos do exercìcio fìsico, e, composição proteica anabólica. | |
ATE227986T1 (de) | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 | |
BRPI0410129A (pt) | uso terapêutico de anticorpos anti-cs1 | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
BRPI0411982A (pt) | glicano de aperfeiçoamento de terapia | |
Dideriksen et al. | Effect of acute exercise on patella tendon protein synthesis and gene expression | |
Joubert et al. | Neuromuscular electrostimulation and insulin sensitivity in patients with type 2 diabetes: the ELECTRODIAB pilot study | |
BR112019019743B1 (pt) | Composições compreendendo neurotoxinas botulínicas e seus usos | |
Szőke et al. | Small molecule somatostatin receptor subtype 4 (sst4) agonists are novel anti-inflammatory and analgesic drug candidates | |
Ljubicic et al. | Specific attenuation of protein kinase phosphorylation in muscle with a high mitochondrial content | |
Dyachenko et al. | α-Conotoxin RgIA and oligoarginine R8 in the mice model alleviate long-term oxaliplatin induced neuropathy | |
Ackermann et al. | Tendon pain–what are the mechanisms behind it? | |
Keen-Rhinehart et al. | Leptin inhibits food-deprivation-induced increases in food intake and food hoarding | |
KR890700606A (ko) | 생물학적 활성분자 | |
Copp et al. | Nitric oxide synthase inhibition during treadmill exercise reveals fiber-type specific vascular control in the rat hindlimb |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |